miR-155-specific siRNA enhances chemosensitivity of Burkitt lymphoma Raji cells to cytosine arabinoside by inducing apoptosis
LIU Ping-ping1, ZHU Jin-can2, ZHENG Li1, LIU Shan-tao2, TAN Guang-xiao2, HE Dong-mei2, LIU Ge-xiu2
1Department of Hematology & Oncology, Tsinghua University First Hospital, Beijing 100016, China; 2Institute of Hematology, School of Medicine, Jinan University, Guangzhou 510632, China.
AIM：To investigate the effect of miR-155-specific siRNA alone or in combination with cytosine arabinoside (Ara-C) on the growth and apoptosis of Burkitt lymphoma Raji cells. METHODS：miR-155-specific siRNA and/or Ara-C were used to treat the cells. Quantitative real-time polymerase chain reaction was used to detect the expression of miR-155. The growth of the cells was analyzed by CKK-8 assay. The cell apoptosis was determined by flow cytometry. RESULTS：The miR-155 expression level of the cells transfected with miR-155 siRNA was significantly lower than that in the 2 control groups. Ara-C or miR-155 siRNA alone inhibited the growth of Raji cells in a dose-depend manner. miR-155 siRNA combined with Ara-C produced more inhibition of cell proliferation (P<0.05). After treatment for 48 h, the apoptotic rate of Raji cells in miR-155 siRNA+Ara-C group ［(38.4±1.4)%］ was higher than that in Ara-C group ［(16.5±0.3)%］ and miR-155 siRNA group ［(14.6±0.3)%］, with statistically significant difference (P<0.05). The expression of caspase-3 in Ara-C+miR-155 siRNA group was increased significantly as compared with Ara-C group and miR-155 siRNA group. CONCLUSION：miR-155-specific siRNA enhances the chemosensitivity of Raji cells to Ara-C by inducing apoptosis through the caspase-3 pathway.
Huang X, Shen Y, Liu M, et al. Quantitative proteomics reveals that miR-155 regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma［J］. Am J Pathol, 2012, 181(1):26-33.
［2］
Rai D, Kim SW, McKeller MR, et al. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis［J］. Proc Natl Acad Sci U S A, 2010, 107(7):3111-3116.
［3］
Dagan LN, Jiang X, Bhatt S, et al. miR-155 regulates HGAL expression and increases lymphoma cell motility［J］. Blood, 2012,119(2):513-520.
［4］
Kopp KL, Ralfkiaer U, Gjerdrum LM, et al. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma［J］. Cell Cycle, 2013, 12(12):1939-1947.
［5］
Pouliot LM, Chen YC, Bai J, et al. Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family［J］. Cancer Res, 2012, 72(22):5945-5955.
［6］
Liu C, Iqbal J, Teruya-Feldstein J, et al. MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma［J］. Blood, 2013, 122(12):2083-2092.
Scherr M, Battmer K, Winkler T, et al. Specific inhibition of bcr-abl gene expression by small interfering RNA［J］. Blood, 2003, 101(4):1566 -1569.
［9］
Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse［J］. Cur Biol, 2002, 12(9):735-739.
［10］
Tam W, Ben-Yehuda D, Hayward WS. bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its nonco-ding RNA［J］. Mol Cell Biol, 1997, 17(3):1490-1502.
［11］
Wang J, Wu J. Role of miR-155 in breast cancer［M］. Front Biosci (Landmark Ed),2012,17:2350-2355.
［12］
Yamanaka Y, Tagawa H, Takahashi N, et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia［J］. Blood, 2009, 114(15):3265-3275.
［13］
OConnell RM, Chaudhuri AA, Rao DS, et al. Inositol phosphatase SHIPl is a primary target of miR-155［J］. Proc Natl Acad Sci U S A, 2009, 106(17):7113-7118.
［14］
Grant S. Ara-C: cellular and molecular pharmacology ［J］. Adv Cancer Res, 1998,72:197-233.
［15］
Wang HQ, Yu XD, Liu ZH, et al. Deregulated miR-155 promotes Fas-mediated apoptosis in human intervertebral disc degeneration by targeting FADD and caspase-3［J］. J Pathol, 2011, 225(2): 232-242.
